Table 6.
Intraprostatic FDG uptake as a predictor of the predicted 5-year progression-free survival by CAPRA-S and MSKCC nonograms
| CAPRA-S* | MSKCC † | |||
|---|---|---|---|---|
| Median % (25th – 75th percentile) | P -value | Median % (25th – 75th percentile) | P -value | |
| Clinical reporting | ||||
| IPFU- | 70.2 (26.7 – 85.2) | 0.008 | 91.5 (77.0 – 97.0) | 0.004 |
| IPFU+ | 25.9 (0.0 – 42.5) | 59.0 (42.0 – 88.0) | ||
| Blinded reading | ||||
| IPFU- (Score 0 or 1) | 70.2 (34.2 – 91.0) | 0.017 | 93.0 (81.0 – 97.5) | 0.010 |
| IPFU+ (Score 2 to 4) | 26.9 (0.0 – 63.3) | 73.0 (45.3 – 89.8) | ||
| Quantitative analysis | ||||
| IPFU- (SUVmax < 4.0) | 70.2 (26.7 – 85.2) | 0.030 | 91.5 (72.8 – 97.0) | 0.020 |
| IPFU+ (SUVmax ≥ 4.0) | 25.9 (0.0 – 42.5) | 72.0 (45.0 – 89.0) | ||
FDG = 18F-fluorodeoxyglucose; IPFU = intraprostatic FDG uptake; IPFU- = IPFU-negative; IPFU + = IPFU-positive; SUVmax = maximum standardized uptake value.
*University of California, San Franciso Cancer of the Prostate Risk Assessment score: Post-Radical Prostatectomy nomogram.
†Memorial Sloan-Kettering Cancer Center post-radical prostatectomy nomogram.